Ohcanbohtosat - Hongfu Cai
- Čájehuvvo 1 - 10 / 10
-
1
Sugemalimab combined with chemotherapy for the treatment of advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis Dahkki Hongfu Cai, Ling Fang, Zhiwei Zheng
Almmustuhtton 2024Hildobáiki: Láddejuvvo…Connect to this object online.
Sajádat: Láddejuvvo…
Girji -
2
Toripalimab plus chemotherapy in the treatment of metastatic triple-negative breast cancer: a cost-effectiveness analysis Dahkki Hongfu Cai, Lisheng Huang, Zhiwei Zheng
Almmustuhtton 2024Hildobáiki: Láddejuvvo…Connect to this object online.
Sajádat: Láddejuvvo…
Girji -
3
Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis Dahkki Hongfu Cai, Ling Fang, Jingwen Lin, Zhiwei Zheng
Almmustuhtton 2024Hildobáiki: Láddejuvvo…Connect to this object online.
Sajádat: Láddejuvvo…
Girji -
4
Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer Dahkki Zhiwei Zheng, Huide Zhu, Ling Fang, Hongfu Cai
Almmustuhtton 2022Hildobáiki: Láddejuvvo…Connect to this object online.
Sajádat: Láddejuvvo…
Girji -
5
Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis Dahkki Zhiwei Zheng, Yuxuan Lin, Yuxuan Lin, Hongfu Cai
Almmustuhtton 2024Hildobáiki: Láddejuvvo…Connect to this object online.
Sajádat: Láddejuvvo…
Girji -
6
Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 1... Dahkki Zhiwei Zheng, Jingrong Lin, Huide Zhu, Hongfu Cai
Almmustuhtton 2022Hildobáiki: Láddejuvvo…Connect to this object online.
Sajádat: Láddejuvvo…
Girji -
7
Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer Dahkki Na Li, Na Li, Huanrui Zheng, Huanrui Zheng, Yanlei Huang, Bin Zheng, Bin Zheng, Hongfu Cai, Hongfu Cai, Maobai Liu, Maobai Liu
Almmustuhtton 2021Hildobáiki: Láddejuvvo…Connect to this object online.
Sajádat: Láddejuvvo…
Girji -
8
Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer... Dahkki Zhiwei Zheng, Liu Yang, Siqi Xu, Huide Zhu, Hongfu Cai
Almmustuhtton 2022Hildobáiki: Láddejuvvo…Connect to this object online.
Sajádat: Láddejuvvo…
Girji -
9
Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma Dahkki Hongfu Cai, Baohua Xu, Na Li, Bin Zheng, Zhiwei Zheng, Maobai Liu
Almmustuhtton 2021Hildobáiki: Láddejuvvo…Connect to this object online.
Sajádat: Láddejuvvo…
Girji -
10
Systematic review and meta-analysis: de novo combination of nucleos(t)ide analogs and pegylated interferon alpha versus pegylated interferon alpha monotherapy for the functional cu... Dahkki Na Wei, Bin Zheng, Hongfu Cai, Na Li, Jing Yang, Maobai Liu
Almmustuhtton 2024Hildobáiki: Láddejuvvo…Connect to this object online.
Sajádat: Láddejuvvo…
Girji